Folic Acid and Vitamin B12 Administration in CKD, Why Not?

Overview

Journal Nutrients

Date 2019 Feb 21

PMID 30781775

Citations 42

Authors

Irene Capelli

Giuseppe Cianciolo

Lorenzo Gasperoni

Fulvia Zappulo

Francesco Tondolo

Maria Cappuccilli

Gaetano La Manna

Affiliations

Soon will be listed here.

Abstract

Patients affected by chronic kidney disease (CKD) or end-stage renal disease (ESRD) experience a huge cardiovascular risk and cardiovascular events represent the leading causes of death. Since traditional risk factors cannot fully explain such increased cardiovascular risk, interest in non-traditional risk factors, such as hyperhomocysteinemia and folic acid and vitamin B12 metabolism impairment, is growing. Although elevated homocysteine blood levels are often seen in patients with CKD and ESRD, whether hyperhomocysteinemia represents a reliable cardiovascular and mortality risk marker or a therapeutic target in this population is still unclear. In addition, folic acid and vitamin B12 could not only be mere cofactors in the homocysteine metabolism; they may have a direct action in determining tissue damage and cardiovascular risk. The purpose of this review was to highlight homocysteine, folic acid and vitamin B12 metabolism impairment in CKD and ESRD and to summarize available evidences on hyperhomocysteinemia, folic acid and vitamin B12 as cardiovascular risk markers, therapeutic target and risk factors for CKD progression.

Citing Articles

Vitamin B12 deficiency in dialysis patients: risk factors, diagnosis, complications, and treatment: A comprehensive review.

Araji G, Keesari P, Chowdhry V, Valsechi-Diaz J, Afif S, Diab W World J Nephrol. 2024; 13(4):100268.

PMID: 39723360 PMC: 11572648. DOI: 10.5527/wjn.v13.i4.100268.

Role of Uremic Toxins in Vascular Inflammation Associated with Chronic Kidney Disease.

Chermiti R, Burtey S, Dou L J Clin Med. 2024; 13(23).

PMID: 39685608 PMC: 11642335. DOI: 10.3390/jcm13237149.

Association between riboflavin intake and the risk of all-cause mortality of patients with chronic kidney disease: A retrospective cohort study.

Ren X, Wang R, Liu F, Wang Q, Chen H, Hou Y Medicine (Baltimore). 2024; 103(39):e39417.

PMID: 39331893 PMC: 11441935. DOI: 10.1097/MD.0000000000039417.

Association between blood methylmalonic acid and chronic kidney disease in the general US population: insights from multi-cycle National Health and Nutrition Examination Survey (NHANES).

Wu L, Chang D, Zhao M, Tang S, Chen M Ann Transl Med. 2024; 12(3):47.

PMID: 38911563 PMC: 11193559. DOI: 10.21037/atm-23-1930.

Serum Vitamin B12 Deficiency in Chronic Hemodialysis Patients.

Mushtaq M, Usmani M, Hameed N, Anwar A, Hashmi A Cureus. 2024; 16(4):e58751.

PMID: 38779272 PMC: 11110947. DOI: 10.7759/cureus.58751.

References

Buccianti G, Porcella A, Valenti G, Como G, Finazzi S, MAIOLO A . Folate measurements in patients on regular hemodialysis treatment. Am J Kidney Dis. 1999; 33(3):492-7. DOI: 10.1016/s0272-6386(99)70186-1. View

Sirrs S, Duncan L, Djurdjev O, Nussbaumer G, Ganz G, Frohlich J . Homocyst(e)ine and vascular access complications in haemodialysis patients: insights into a complex metabolic relationship. Nephrol Dial Transplant. 1999; 14(3):738-43. DOI: 10.1093/ndt/14.3.738. View

Dierkes J, Domrose U, Ambrosch A, Schneede J, Guttormsen A, Neumann K . Supplementation with vitamin B12 decreases homocysteine and methylmalonic acid but also serum folate in patients with end-stage renal disease. Metabolism. 1999; 48(5):631-5. DOI: 10.1016/s0026-0495(99)90062-8. View

Bostom A, Gohh R, Liaugaudas G, Beaulieu A, Han H, Jacques P . Prevalence of mild fasting hyperhomocysteinemia in renal transplant versus coronary artery disease patients after fortification of cereal grain flour with folic acid. Atherosclerosis. 1999; 145(1):221-4. DOI: 10.1016/s0021-9150(99)00023-4. View

Kunz K, Petitjean P, Lisri M, Chantrel F, Koehl C, Wiesel M . Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: is homocyst(e)ine the missing link?. Nephrol Dial Transplant. 1999; 14(8):1934-42. DOI: 10.1093/ndt/14.8.1934. View

van Guldener C, Kulik W, Berger R, Dijkstra D, Jakobs C, Reijngoud D . Homocysteine and methionine metabolism in ESRD: A stable isotope study. Kidney Int. 1999; 56(3):1064-71. DOI: 10.1046/j.1523-1755.1999.00624.x. View

Manns B, Burgess E, Hyndman M, Parsons H, Schaefer J, Scott-Douglas N . Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am J Kidney Dis. 1999; 34(4):669-77. DOI: 10.1016/S0272-6386(99)70392-6. View

Beaulieu A, Gohh R, Han H, Hakas D, Jacques P, Selhub J . Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients. Arterioscler Thromb Vasc Biol. 1999; 19(12):2918-21. DOI: 10.1161/01.atv.19.12.2918. View

Seetharam B, Li N . Transcobalamin II and its cell surface receptor. Vitam Horm. 2000; 59:337-66. DOI: 10.1016/s0083-6729(00)59012-8. View

10.

Suliman M, Qureshi A, Barany P, Stenvinkel P, Filho J, Anderstam B . Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int. 2000; 57(4):1727-35. DOI: 10.1046/j.1523-1755.2000.00018.x. View

11.

Bostom A, SHEMIN D, Bagley P, Massy Z, Zanabli A, Christopher K . Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Circulation. 2000; 101(24):2829-32. DOI: 10.1161/01.cir.101.24.2829. View

12.

Tremblay R, Bonnardeaux A, Geadah D, Busque L, Lebrun M, Ouimet D . Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins. Kidney Int. 2000; 58(2):851-8. DOI: 10.1046/j.1523-1755.2000.00234.x. View

13.

Brattstrom L, Wilcken D . Homocysteine and cardiovascular disease: cause or effect?. Am J Clin Nutr. 2000; 72(2):315-23. DOI: 10.1093/ajcn/72.2.315. View

14.

Homberger A, Linnebank M, Winter C, Willenbring H, Marquardt T, Harms E . Genomic structure and transcript variants of the human methylenetetrahydrofolate reductase gene. Eur J Hum Genet. 2000; 8(9):725-9. DOI: 10.1038/sj.ejhg.5200522. View

15.

Title L, Cummings P, Giddens K, Genest Jr J, Nassar B . Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol. 2000; 36(3):758-65. DOI: 10.1016/s0735-1097(00)00809-3. View

16.

Dierkes J, Domrose U, Westphal S, Ambrosch A, Bosselmann H, Neumann K . Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation. 2000; 102(16):1964-9. DOI: 10.1161/01.cir.102.16.1964. View

17.

Chambers J, Ueland P, Obeid O, Wrigley J, Refsum H, Kooner J . Improved vascular endothelial function after oral B vitamins: An effect mediated through reduced concentrations of free plasma homocysteine. Circulation. 2000; 102(20):2479-83. DOI: 10.1161/01.cir.102.20.2479. View

18.

Poddar R, Sivasubramanian N, Dibello P, Robinson K, Jacobsen D . Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular disease. Circulation. 2001; 103(22):2717-23. DOI: 10.1161/01.cir.103.22.2717. View

19.

Foley R, Parfrey P, Sarnak M . Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 2001; 9(12 Suppl):S16-23. View

20.

Zhang C, Cai Y, Adachi M, Oshiro S, Aso T, Kaufman R . Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. J Biol Chem. 2001; 276(38):35867-74. DOI: 10.1074/jbc.M100747200. View